ABSTRACT -Pituitary carcinomas are rare neoplasms characterized by craniospinal and/or systemic metastases originated from the pituitary. Their histopathology is frequently indistinguishable from that of benign adenomas. The development of markers that better reflect their behavior is desirable. We present the case of a 47 year-old man with a pro l a c t i n -s e c reting macroadenoma who was submitted to surgeries, cranial radiation therapy, and bromocriptine treatment, but evolved to a fatal outcome after the disclosure of int r a c r anial metastases. Tumor samples underwent p53 and Ki-67 immunohistochemical assessment. p53 was absent in all samples, a rare finding among pituitary carcinomas. Ki-67 proliferative index was 2.80% in the original tumor, 4.40% in the relapse, and 4.45% in the metastasis. The figure in the relapse is higher than the expected for a noninvasive adenoma. In conclusion, p53 staining is not positive in all pituitary carc i n o m a s . A high Ki-67 proliferative index in a pituitary adenoma might indicate a more aggressive behavior.
The prevalence of clinically overt pituitary tumors is around 0.02% of the population 1 . Most are m i c roadenomas (<10 mm), exhibit benign behavio r, and produce one of the hormones secreted by the normal gland. Relatively few people develop m a c ro a d e n o m a s 2 , usually with a benign phenotype, but that can occasionally become aggressive, i nfiltrating adjacent stru c t u res and re c u rring re p e a tedly despite conventional treatment (invasive aden o m a s ) 3 , 4 . Rare l y, adenomas present even more a g g re s s i v e l y, developing intracranial and/or e x t r a c r anial metastases (pituitary carcinomas). The pre s e nce of tumor tissue not contiguous with sella turc ica is a condition re c q u i red for diagnosis of a pituit a ry carc i n o m a 5 . Its prevalence is estimated aro u n d 0.1-0.2% of all cases of neoplasms of this gland 6 .
Few more than 140 cases of pituitary carc i n o m a s have been re p o rted in the literature 7 , 30% of them represented by prolactin-secreting tumors 8 . The etiology of pituitary carcinomas is poorly understood and their histology is generally indistinguishable from that of benign adenomas 9 -1 1 . Such factors added to the poor response of such neoplasms to cytotoxic chemotherapy and their fatal o u t c o m e 7 , 1 1 -1 3 place a challenge towards more precocious diagnosis or suspicion of aggressive behavio r 1 3 . Survival after documentation of metastatic disease is poor; 66% of patients die within 1 year . However, it re m a i n s a theoretical issue whether such immunohistochemical analysis could identify a trend for local invasion or metastatic dissemination when applied to patients with macroadenomas.
CASE
A 47-year-old white man initiated with re c u rrent e p isodes of dizziness and vomiting in 1994. Some months l ater a moderate sustained fronto-temporal headache, d rowsiness, and a defect on the visual fields have appeare d . F u rther health problems were smoking, obesity, hyperlipidemia, and erectile dysfunction of recent onset. On M a rch 1995 a neuro s u rgeon ord e red a computed tomography (CT scan) of the head that exhibited a slight brain a t rophy and a space-occupying lesion in sella turc i c a with 2.5 cm on its largest diameter, invading suprasell a r c i s t e rn (Fig 1) . Serum prolactin level was higher than 3 , 0 0 0 ng/ml (Table 1) , and the rest of his endocrinal profile w a s not evaluated at that time. The patient was submitted to a surgical intervention through transsphenoidal app roach on April 1995. Histopathological examination c o n f i rmed a pituitary adenoma. The prolactin dro p p e d after surg e ry (on the second day it was 634.4 ng/ml) accompanied by the gradual abatement of the symptoms.
On November 1995 a new CT scan demonstrated a tumoral relapse with 1.7 cm on its larger diameter, still invading suprasellar cistern. Further CT scans perf o rm e d 9 and 23 months later evidenced little additional gro w t h . At the end of 1997 the patient looked for assistance by our group. He was still complaining about visual diff i c u lt y. Examination of the visual fields showed upper bitemporal quadrantanoptic defect. The serum prolactin level was 2,717 ng/ml (Table) . A new surgical pro c e d u re w a s u n d e rtaken, this turn by transcranial approach (November 1997). Even though the normalization of the visual fields and a great fall in serum prolactin level have h a ppened, the latter did not return to normal range.
On March 1998 a tumoral mass with a slight suprasellar prominence was again manifest on a CT scan, and serum prolactin level raised up to 1,025 ng/ml. The patient was then re f e rred to radiation theraphy, and received 50 Gy of external beam radiation in 35 fractions to sella throughout 40 days. Some months later (August 1999) re m a r kable decrease of tumoral dimensions on a new CT scan and of serum prolactin levels was evident (Table) . A magnetic resonance imaging (MRI) scan of brain and pituitary gland perf o rmed on June 2000 comproved the re d u c t i o n in tumor size: there was just a small intrasellar spot that had high signal on T2 and was less contrast-enhancing than the rest of the gland, a finding that was interpre ted as a surgical sequel or a small persistent tumor.
Since 1999 treatment with bromocriptine and hormone replacement (thyroxine, prednisone, testostero n e , and vasopressin) were carried out, the latter due to a h o rmonal pattern of panhypopituitarism. Adverse eff e c t s (nausea, stomacache) attributed to the increasing daily doses of bromocriptine employed since 2000 made t h e patient unwilling to accept the therapy. From May to August 2000 he was submitted to a trial with carbegoline 1 mg a week, but serum prolactin level still rose ( f ro m 230.4 ng/ml to 413.0 ng/ml). On October 2000 he re f u s e d the re t u rn to high doses of bromocriptine proposed by medical staff (17.5 mg a day) and quit accompaniment. Even so, he kept the use of hormone replacement and a low daily dose of bromocriptine (5 mg).
On April 2001 the patient started to feel an intense pain on lumbar region with spread to the posterior aspect on the right lower limb, what led him to consult an o rthopedist. A CT scan of lumbar spine showed an image suggestive of lumbar interv e rtebral disk prolapse on L5-S1 level. Surgical decompression was undertaken and t h e disk prolapse was confirmed and excised. However, dur- ing the pro c e d u rethe patient suff e red cardiac arrh y t hmia followed by cardiac arrest that re q u i red more than 20 minutes to be reversed. After that, he exhibited an anoxic-ischemic encephalopathy: bilateral Babinski's sign, limb withdrawal to pain, no verbal response, spont aneous eye openning, no evident brain stem damage, a n d myoclonic jerks in limbs and face. Neurological accompaniment by our staff was then solicited. A CT scan of the head disclosed a surprising finding: multiple hyperintense lesions with slight contrast enhancement scattered o n left cerebral hemisphere convexity (Fig 2) . No evident t umor in sella or parasellar region was detected.
In the following days a MRI scan of brain and pituit a ry gland confirmed the presence of the lesions and absence of a sellar mass. A biopsy of one of the meningeal tumors revealed a pituitary adenoma. The contemporary serum prolactin level was 2,373.0 ng/ml (Table) . Evolution was unfavourable, with installation of pneumonia and renal insuff i c i e n c y. Cardiovascular status remained critical, without evidence of myocardial infarc- All tumor samples showed the appearance of a benign pituitary adenoma on standard histopathological examination, with a difuse (solid) pattern constituted by round cells with a predominantly basophilic cytoplasm. Nuclear pleomorphism, cytological atypia, and necro s i s w e re not detected, while mitotic figures were rare. Immunostaining for pituitary hormones was positive only for the prolactin in the three samples, whereas p53 staining was negative in all of them. Ki-67 staining was detected in all samples with the labeling indices bellow: 2.80% in original tumor (1995), 4.40% in relapse (1997), and 4.45% in metastasis (2001) (Fig 3) .
DISCUSSION
P resent re p o rt shares many similarities with previous published cases of pituitary carcinomas. Fro m the initial diagnosis of the macroadenoma to the d i s c l o s u re of metastatic disease a long interval of seven years has passed. In a series of 15 cases this l atency period ranged from 4 months to 18 years, with the mean of 6.6 years 8 . According to another study, this period is 9.5 years for ACTH-producing lesions and 4.7 years for PRL-secreting tumors 7 . Vi rt u a l l y all pituitary carcinomas arose from macro a d e n om a s 8 , 1 1 and most were submitted to one and, in m any times, two surgical approaches and radiation t h erapy years before appearance of metastases. In this setting, the process of origin seems like a malignant transform a t i o n 1 1 . Radiation therapy and surgical interventions are pointed by some authors as possible causes of such change in behavior 1 2 , 1 5 , 1 6 . By the way, the patient with the longest latency period (18 years) in that series was the only who did not undego cranial surgery 8 .
A profile of resistance to bromocriptine action denoted by the increase in serum prolactin levels after some months or years of pharm a c o l o g i c a l t reatment is also a common characteristic among metastatic prolactinomas. This may re p resent a clue for suspition of an aggressive behavior, but is neither a specific nor an early manifestation. By the time of rise in prolactin levels in present case, no metastatic disease was evident on a MRI scan of brain (June 2000). Nevertheless, it became patent on a CT scan ten months later. Immunostaining for pituitary hormones in the present case re i nf o rced diagnosis of prolactinoma. The pro p o rt i o n of horm o n e -p roducing tumors among pituitary carcinomas is reported to be around 74%, represented mostly by the prolactin-or ACTH-secre t i n g s u b t y p e s 8 , 1 1 . In fact, malignant prolactinomas perform 30% of pituitary carcinomas 8 .
Although histology of metastatic deposits in many cases tends to appear more aggressive than p r i m a ry tumor 1 1 , the aspect is commonly indistinguishable from that of benign adenomas 1 0 , 1 1 , 1 7 , even on ultrastructural gro u n d s 9 . Traditional histopathological features of malignancy (mitotic figures, nuclear pleomorphism, high cellularity, cytological atypias, presence of necrosis) are uncommon. When mitotic figures are present, they do pro v i d e some indication of the behavior and invasive potential of pituitary tumors, but for routine diagnostic purposes, however, discriminating power of this parameter is somewhat limited 1 8 . This discre p a ncy between clinical and pathological characterist i c s has led to a search for markers more informative of the behavior of pituitary carcinomas. For instance, a myriad of genetic mutations has been re p o rted in such tumors 1 2 , 1 9 -2 1 , but their assessment has shown little, if any, clinical usefulness 1 2 . Besides, several biochemical and histopathological markers have recently been investigated in order to evalu- ate the etiopathology of pituitary carcinomas, but still without conclusive results [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] .
In the last years an increasing amount of data about immunohistochemical assessment of the exp ression for mutant protein of p53 gene and for K i -67 (MIB-1) antigen expressed during cellular pro l iferation has suggested that such immunostainings may be promising markers of a malignant behavior in pituitary neoplasms. p53 is a nuclear pro t e i n encoded by a gene located on chro m o s s o m e 17p13.1, a tumor suppressor gene 7 . Its alteration makes it act as a dominant oncogene. The gene is found mutated and/or deleted in a wide range of tumors, predominantly malignant 1 4 . . It is discussed whether technical diff e rences could be responsible for variable findings among studies 1 0 , 3 3 . N e v e rtheless, absent p53 immunostaining in pitui t a ry carcinomas was recently re p o rt e d 2 6 , 3 2 , 3 4 , a finding also encountered by our group. This suggests that this method is not so sensitive as first imagi n e d .
New histochemical methods of growth fraction determination were developed in last decades in o rder to provide rapid and cheap means of gauging pituitary tumor behavior. One of the most promising of these is detection of Ki-67 antigen, a p roliferation marker that is selectively expressed during G1, S1, G2, and M phases of cell cycle 8 , 1 8 , 3 1 , 3 5 . It can be assessed through the use of the MIB-1 immunostaining, the antibody against the Ki-67 for the paraffin pre p a r a t i o n s Vi rtually all noninvasive adenomas have a gro w t h fraction of less than 3% 1 1 . On the other hand, growth fractions are significantly higher among i n v a s ive adenomas, and the highest among pituitary c a rcinomas, when compared to noninvasive adenomas (4.7%, 11.9%, and 1.4%, re s p e c t i v e l y ) 3 6 . Indeed, p53-positive pituitary tumors (carcinomas and invasive adenomas) had four times higher indices of MIB-1 staining than p53-negative neoplasms 1 0 . The present case shows a MIB-1 index of 2.80% in original tumor (1995) . However, the figure reached 4.40% in the relapse (1997) and 4.45% in the metastatic deposit (2001). That is, there was an unexpected rise between first and second surgeries.
Even though such immunohistochemical stainings could better reflect the behavior of pituitary tumors, it remains unknown wheter those markers could lead to an early suspicion of a malignant transformation when applied to patients with macroadenomas. In case this hypothesis is true, positiveness for p53 or a high MIB-1 index could serv e as signs indicating that a macroadenoma is likely to metastatize or become locally aggressive. For instance, the present case shows a higher than expected MIB-1 index at the second intervention, w h e n neither evidence of local invasion nor of metastatic dissemination were present. Some authors consider the concept that primary tumors that exhibit mitotic activity, an increased (> 3%) MIB-1 labeling index, and/or p53 immunoreactivity should be t e rmed "atypical adenomas" to denote their a g g re ssive potential and the possibility of future malignant transform a t i o n 3 5 . Would it indicate the need of a more aggressive tretment, like chemotherapy, to prevent local invasion or metastases? This question could be answered with aid of pro s p e c t i v e studies that assess p53 and MIB-1 stainings ro utinely in every surgical intervention for pituitary a d enomas, since all knowledge about the issue is based on re t rospective and, perhaps, selected cases.
In conclusion, pituitary carcinomas re p resent a r a re neoplasm with fatal outcome, for which p53 and MIB-1 immunostainings emerged as clues for a better assessment of tumor behavior. However, not all pituitary carcinomas show positiveness for p53. On the other hand, a higher than expected Ki-67 proliferative index in a pituitary adenoma might alert to the possibility of a more aggre s s i v e behavior.
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